Newsroom

TORONTO--(BUSINESS WIRE)--Chemtrade Announces Record Quarterly Adjusted EBITDA for Q3 2025; Increases Full-Year 2025 Guidance to Record Adjusted EBITDA of Above $503 Million...

TORONTO--(BUSINESS WIRE)--C'est la mise en œuvre, et non le choix du produit, qui est le facteur déterminant du succès d'un logiciel pour les entreprises canadiennes. Selon le Capterra’s 2026 Software Buying Trends Report, seuls 40 % des acheteurs de logiciels canadiens se disent satisfaits de leur achat, tandis que 89 % de ceux qui ont rencontré des problèmes de mise en œuvre ont par la suite regretté leur décision. Les résultats suggèrent que les perturbations lors du déploiement sont non seu...

ST. JOHN’S, Newfoundland and Labrador--(BUSINESS WIRE)--Altius Minerals Corporation (TSX: ALS; OTCQX: ATUSF) (“Altius” or the “Corporation”) reports its Q3 2025 revenue of $17.2 million compared to $13.0 million in Q3 2024. Attributable royalty revenue(1) of $21.4 million ($0.46 per share(1)) compares to $14.7 million ($0.32 per share) reported in Q3 2024. The current quarter reflects higher attributable potash volumes and copper stream deliveries at Chapada as well as higher interest and inves...

LONDRA--(BUSINESS WIRE)--Prokarium, un'azienda biofarmaceutica di fase clinica all'avanguardia nel campo dell'immunoterapia microbica, ha annunciato oggi la nomina di Ibs Mahmood al ruolo di Chief Executive Officer (CEO). Ibs subentrerà a Kristen Albright, che entrerà a far parte del Consiglio di amministrazione per continuare a definire l'orientamento strategico di Prokarium. Ibs vanta 25 anni di esperienza come imprenditore in ambito biotecnologico, durante i quali ha fondato e guidato divers...

LONDRES--(BUSINESS WIRE)--Prokarium, une biopharma de phase clinique pionnière dans le domaine de l'immunothérapie microbienne, annonce ce jour la nomination d'Ibs Mahmood au poste de CEO. Ibs succède à Kristen Albright, qui rejoindra le conseil d’administration pour continuer à façonner l’orientation stratégique de Prokarium. Ibs apporte 25 ans en tant qu'entrepreneur en biotechnologie ayant fondé et dirigé plusieurs entreprises de sciences de la vie via le développement clinique, le financeme...

ROCHESTER, Minn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology compa...

LONDEN--(BUSINESS WIRE)--Prokarium, een biofarmaceutisch bedrijf in de klinische fase dat pioniert op het gebied van microbiële immunotherapie, heeft vandaag de benoeming van Ibs Mahmood tot Chief Executive Officer (CEO) aangekondigd. Ibs volgt Kristen Albright op, die toetreedt tot de Raad van Bestuur om de strategische richting van Prokarium verder vorm te geven. Ibs heeft 25 jaar ervaring als biotechnologisch ondernemer en heeft meerdere life science-bedrijven opgericht en geleid op hun traj...

CINCINNATI--(BUSINESS WIRE)--American Financial Group, Inc. (NYSE: AFG) announced today that Carl H. Lindner, III, Co-CEO, American Financial Group and David L. Thompson, President & Chief Operating Officer, Great American Insurance Group, along with Brian S. Hertzman, Senior Vice President & Chief Financial Officer, American Financial Group, will meet with investors in a forum hosted by Dowling & Partners in New York City at 1:00 p.m. (ET) on Thursday, November 20, 2025. The invest...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Class A (ticker: “WESFX”), Class C (ticker: “WEFCX”), and/or Class I (ticker: “WEIFX”) shares of the Wildermuth Fund between November 1, 2020 and June 29, 2023, both dates inclusive (the “Class Period”). The Wildermuth Fund (a.k.a the “Wildermuth Endowment Fund and Wildermuth Endowment Strategy Fund”) is a closed-end fund that invested in a variety of asset c...

SEATTLE--(BUSINESS WIRE)--Today, the Board of Directors of WaFd, Inc. (Nasdaq: WAFD) (the “Company”), announced a regular quarterly cash dividend of 27 cents per share. The dividend will be paid December 5, 2025, to common shareholders of record as of November 21, 2025. This will be the Company’s 171st consecutive quarterly cash dividend. WaFd, Inc. is the parent company of WaFd Bank, a federally insured Washington state chartered commercial bank that operates branches in Washington, Oregon, Id...